Charles River Laboratories (NYSE: CRL) — Perfil da empresa, notícias e dados financeiros
Charles River Laboratories provides essential products and services to accelerate drug discovery in life sciences.
Charles River Laboratories
Charles River Laboratories is a global contract research organization specializing in non-clinical preclinical and clinical laboratory services, research animal models, and gene therapy solutions. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and academic institutions worldwide accelerate drug discovery and clinical development. Its business operations span research models and services, discovery and safety assessment, and manufacturing solutions, including cell and gene therapy contract development and manufacturing, microbial testing, and biologics testing. Headquartered in Wilmington, Massachusetts, the organization supports the safety and efficacy evaluation of pharmaceutical treatments globally.
Resumo
Operações
Produtos e/ou serviços de Charles River Laboratories
- Research Models and Services: Supplies purpose-bred research animal models, including genetically engineered mice and rats, along with colony management, health surveillance, and custom breeding services to biopharmaceutical and academic research institutions across North America, Europe, and Asia.
- Discovery Services: Delivers target identification, hit-to-lead optimization, and in vitro and in vivo pharmacology testing across therapeutic areas such as oncology, neuroscience, and immunology to support early-stage drug development pipelines before clinical evaluation.
- Safety Assessment and Toxicology: Conducts non-GLP and GLP-compliant preclinical safety, toxicology, carcinogenicity, and pathology evaluations, providing data required for Investigational New Drug and New Drug Application submissions to regulatory authorities including the FDA and EMA.
- Biologics Testing Solutions: Provides cell bank characterization, viral clearance studies, lot release testing, and adventitious agent detection services supporting biopharmaceutical products from early development through commercial release across global testing facilities.
- Cell and Gene Therapy CDMO Solutions: Offers contract development and manufacturing organization services for viral vectors, plasmid DNA, and cell therapy products, assisting biotechnology clients in producing clinical- and commercial-grade advanced therapy medicinal products.
- Microbiology Quality Control Solutions: Provides rapid microbial detection systems, endotoxin testing reagents, automated instrumentation, and strain identification services to ensure sterility and quality control in pharmaceutical and medical device manufacturing environments.
equipe executiva do Charles River Laboratories
- Birgit GirshickCEO & Director
- Michael Gunnar KnellCorporate Senior VP & Chief Accounting Officer
- Joseph W. LaPlumeCorporate Executive Vice President of Corporate Development & Strategy
- Victoria L. CreamerCorporate Executive VP & Chief People Officer
- Glenn G. ColemanCorporate Executive VP & CFO
- Mark MintzCorporate EVP, Chief Information Officer & Global Shared Services
- Todd SpencerCorporate Vice President of Investor Relations
- Kerry DaileyCorporate Senior VP & Chief Legal Officer
- Amy E. CianciarusoCorporate Senior Vice President, Chief Communications Officer & Government Relations
- Brian F. BathgateCorporate Senior Vice President of European Safety Assessment
Principais indicadores financeiros
Resultados divulgados pela Charles River Laboratories, em USD.
- Cap. de mercado
- 17,3 bi
- Receita (TTM)
- 4 bi
- P/L
- —
- LPA (diluído, TTM)
- -4.8
- Dividend yield
- —
- Margem de lucro
- -6.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 4 bi | 507,8 mi | -144,3 mi | |
| 4 bi | 227,3 mi | 10,3 mi | |
| 4,1 bi | 617,3 mi | 474,6 mi | |
| 4 bi | 651 mi | 486,2 mi |